Alkermes plc (FRA:8AK)

Market Cap	4.47B -8.5%
Revenue (ttm)	1.30B +1.1%
Net Income	288.78M +1.6%
EPS	1.72 +2.4%
Shares Out	n/a
PE Ratio	15.49
Forward PE	17.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	26.80
Previous Close	26.80
Day's Range	26.80 - 26.80
52-Week Range	22.00 - 34.00
Beta	n/a
RSI	44.26
Earnings Date	Feb 25, 2026

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 1,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AK

Financial Performance

In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.

Financial numbers in USD